Navegando por Palavras-chave "benzodiazepínicos"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Clonazepam, um campeão de vendas no Brasil. Por quê?
    (Universidade Federal de São Paulo (UNIFESP), 2016-06-01) Cruz, Nelma Lourenco de Matos [UNIFESP]; Carlini, Elisaldo Luiz de Araujo [UNIFESP]; http://lattes.cnpq.br/5948335656347039; http://lattes.cnpq.br/8459051263596166; Universidade Federal de São Paulo (UNIFESP)
    Clonazepam, a benzodiazepine, is the leading seller in Brazil and the most consumed version of Ordinance 344/98. It is used in the treatment of central nervous system disorders including epilepsy, anxiety, social phobia, insomnia, affective bipolar disorders, panic disorders and akathisia. Clonazepam has high therapeutic efficacy, low toxicity and can lead to dependence after six to eight weeks of use – withdrawal symptoms may occur if there is abrupt discontinuation of use, even in therapeutic doses. This study aims to analyse the various reasons for high sales and consumption of the drug in Brazil. Methodology: the high consumption of clonazepam is a phenomenon of unknown causes and effects; therefore, qualitative research was employed. The focus groups of nineteen patients, five doctors and four pharmacists was formed within two research sites: Funilândia (Minas Gerais) and São Paulo (São Paulo). Interviews were conducted with semi-structured scripts and content analysis with the help of NVivo software. Results – Patients: After use of Clonazepam, patients declared feeling symptoms of sleepiness, relaxation, comfort and security. The range of dosage patients self-administer can be dependent on the emotional state of the users, who do not report taking high doses of clonazepam. The period of use of the drug among patients was up to fifteen years. Information is exchanged between users, and many of them are friends or relatives. Many of them reported being able to get a prescription for clonazepam without receiving medical consultation. Many patients also tried to stop the use of the drug, but were not able to. All of them reported never having received guidance from pharmacists, and only a few received instruction from doctors. Doctors: The main stated reason for prescribing the drug to patients was “renewing a previous prescription from another doctor”. They also declared that were aware of the dosage flexibility, but that the patients do not abusive it. Doctors trust the drug and find it safe, believing that patients use Clonazepam in order to treat ‘problems’. Pharmacists: Pharmacists do not feel co-responsible for the prescription of Clonazepam. They believe that the control of sales of the drug is inefficient and easy to get around – there have been sales of the drug without the correct prescription produced. One of the pharmacists in the study declared that they sell the drug without prescription, something that was witnessed during during the interview. Pharmaceutical laboratories - were not forthcoming in their interest to be a part of the research, and they refused the invitation to participate. Conclusions: The abuse and misuse of Clonazepam is a public health problem. The results of the research indicate failure in the use, the prescription, and the control of sales of Clonazepam. It is necessary to restructure systems that monitor the production, prescription and sales of the drug. Refresher training for health professionals should be encouraged in order to promote rational and sensible use of medicines, especially in the case of psychotropic medicine. Finally, there should be further promotion of actions aimed at users of Clonazepam seeking to educate them about the benefits and risks of using such drugs, self-medication and appropriate use of medicines.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Tratamento da síndrome de abstinência alcoólica São Paulo 2013
    (Universidade Federal de São Paulo (UNIFESP), 2014-02-26) Yamashiro, Alberto Shodi [UNIFESP]; Mari, Jair de Jesus Mari [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Este estudo tem como objetivo a atualização do tratamento para Síndrome de Abstinência Alcoólica (SAA) tendo em vista o melhor custo-benefício, com base em estudos de revisão sistemática e meta-análise além de ensaios clínicos não incluídos nas últimas revisões disponíveis na literatura. A escolha do benzodiazepínico no tratamento da SAA é adequada devido à efetividade na melhora dos sintomas e baixo custo de tratamento. Diazepam e clordiazepóxido são úteis para manutenção de níveis terapêuticos consistentes, pois tem a meia vida prolongada e proporcionam controle mais efetivo da SAA e maior eficácia na prevenção do delirium. Pacientes idosos ou com disfunção hepática podem se beneficiar de drogas com meia vida intermediária como lorazepam. Para países de média e baixa renda em que não se tem a possibilidade de se monitorar a função hepática do paciente o lorazepam também é uma opção adequada. Summary: